Cassava Sciences, Inc.
SAVA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $89 | $68 | $0 |
| Gross Profit | $0 | -$89 | -$68 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $70 | $89 | $69 | $25 |
| G&A Expenses | $72 | $17 | $12 | $8 |
| SG&A Expenses | $72 | $17 | $12 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$89 | -$69 | $0 |
| Operating Expenses | $141 | $17 | $12 | $33 |
| Operating Income | -$141 | -$106 | -$80 | -$33 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $117 | $9 | $4 | $0 |
| Pre-Tax Income | -$24 | -$97 | -$76 | -$32 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$24 | -$97 | -$76 | -$32 |
| % Margin | – | – | – | – |
| EPS | -0.53 | -2.32 | -1.8 | -0.81 |
| % Growth | 77.2% | -28.9% | -122.2% | – |
| EPS Diluted | -0.52 | -2.32 | -1.8 | -0.81 |
| Weighted Avg Shares Out | 46 | 42 | 40 | 39 |
| Weighted Avg Shares Out Dil | 47 | 42 | 40 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $8 | $3 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $2 | $1 | $1 |
| EBITDA | -$141 | -$104 | -$79 | -$32 |
| % Margin | – | – | – | – |